Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 13, 2022

Primary Completion Date

June 21, 2023

Study Completion Date

June 21, 2023

Conditions
Bipolar DisorderBipolar I DisorderBipolar II Disorder
Interventions
DRUG

N-Acetyl cysteine

Group A and Group B will receive N-Acetylcysteine (NAC). Group A will receive NAC as their first 14 day condition and Group B will receive NAC as their second 14 day condition. Participants will take NAC for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).

DRUG

Placebo

Group A and Group B will receive Placebo. Group A will receive Placebo as their first 14 day condition and Group B will receive Placebo as their second 14 day condition. Participants will take Placebo Oral Capsule for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).

Trial Locations (1)

29425

Medical University Of South Carolina, Charleston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Milken Institute

OTHER

lead

Medical University of South Carolina

OTHER

NCT05340504 - Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder | Biotech Hunter | Biotech Hunter